Deoxyuridine

Deoxyuridine

SCHEMBL4847464

O=c1ccn([C@H]2C[C@H](O)[C@H](CO)O2)c(=O)[nH]1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DUT P33316 3/20 0.64
TK1 P04183 3/20 0.62
LMNA P02545 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
SLC28A1 O00337 1/20 0.60
SLC28A2 O43868 1/20 0.60
SLC29A1 Q99808 1/20 0.60
SLC28A3 Q9HAS3 1/20 0.60
ALOX12 P18054 1/20 0.58
ADRA1A P35348 1/20 0.58
TK2 O00142 1/20 0.57
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
TSHR P16473 1/20 0.56
BLM P54132 1/20 0.56
PMP22 Q01453 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deoxyuridine SCHEMBL9219261 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL2641582 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL889540 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL114598 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL19841232 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL9708874 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL24512520 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL391224 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL9219265 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL28844 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439351-B2 2′ or 3′ -deoxy and 2′, 3′-dideoxy-β-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents THE UAB RESEARCH FOUNDATION (US) 2008-10-21 US disclosed
US-20050101776-A1 2' or 3' -deoxy and 2' , 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents GOSSELIN GILLES (FR) 2005-05-12 US disclosed
EP-0717748-B1 2' OR 3'-DEOXY AND 2'-DIDEOXY-BETA-L-PENTAFURANONUCLEOSIDE COMPOUNDS, METHOD OF PREPARATION AND APPLICATION IN THERARY, ESPECIALLY AS ANTI-VIRAL AGENTS CENTRE NAT RECH SCIENT (FR) 1997-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101776-A1 2' or 3' -deoxy and 2' , 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents DUT, DCTD, DERA DUT 1/4885TK1 40/4885LMNA 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.